Our History

2007

April Official registration of Raifarm Company and launch of our first office in Moscow
May First client contracts signed
August Launch of our first office in Kiev, Ukraine

 

2008

March Completion of first drug registration in Russia
July Completion of first drug registration in Ukraine
September Launch of Almaty, Kazakhstan office

 

2009

March Completion of first drug registration in Kazakhstan
June Launch of New York, USA office
November Completion of first medical device registration in Russia
December Completion of first dietary supplement registration

 

2011

March Registration of first cosmetic product in Russia
September Sales begin for Raifarm’s own product line in Russia
November Launch of our first exclusive marketing project for a cardio product in Russia
December Sales launch of Raifarm products in Kazakhstan
December First product registrations in CIS countries (excluding Russia, Ukraine, and Kazakhstan)
December Successful completion of 300th regulatory project

 

2012

January Sales launch of Raifarm products in Ukraine
March Launch of Copharm Company to provide marketing services for pharma product promotion in Russia
June Sponsorship of medical reward "Prizvanie" in Russia
September Product line extension in Kazakhstan, including introduction of drug, Angiox
October Acquisition of 100th client

 

2013

April Sales launch of Neo-Penotran group of drugs in Russian
July Sales launch of Neo-Penotran group of drugs in Kazakhstan
July Registration of 100th pharmaceutical product
February Successful completion of 500th project
November Successful completion of 600th project
December Registration of 10th medical device belonging to 2b-3 class of risk

2014

June 75% of market in value reached by Angiox, in the segment of antithrombotic agents for stent angioplasty
September Sale of the 1,000,000th pack of Neo-Penotran group of drugs
December Acquisition of 125th client
December Sale of Copharm to Swiss company Acino Pharma AG

2015

March Successful completion of 700th project
June Registration of 125th pharmaceutical product

2016

January Signing of first contract for product registration in the EU
January Signing of first contract for product registration in Turkey
March Successful completion of 800th project
May Signing of first contract for support of Russian GMP inspection

2017

March Successful completion of 900th project
March Successful completion of first Russian GMP inspection
March Acquisition of 150h Client
May Registration of 20th medical device belonging to 2b-3 class of risk
June Receipt of our 1,000th order

2018

January Registration of 145th pharmaceutical product
February Start of 1100th consulting project
February Receipt of 15th GMP certificate
March Start of 35th Russian GMP inspection
April Acquisition of 160th Client
April Competition of 20th Russian GMP inspection
May Successful completion of 1000th project
June Registration of 150th pharmaceutical product
September New service added: Mock Audit before GMP inspection
September Start of 50th Russian GMP inspection
September Acquisition of 165th Client
October Competition of 30th Russian GMP inspection

2019

Acquisition of 170th Client

February: Acquisition of 170th Client  
May: Acquisition of 175th Client
August: Completion of 50th GMP inspection
September: Acquisition of 180th Client
November: Completed 5th GMP mock audit
November: Acquisition of 185th Client

2020

January: Acquisition of 190th Client
March: Completion of 60th GMP inspection
September: Completion of 70th GMP inspection
December: Acquisition of 200th Client

2021

May: Acquisition of 205th Client
May: Completion of 80th GMP inspection
May: Completion of 1100th project
July: Acquisition of 210th Client
November: Acquisition of 215th Client

2022

April: 1st drug registered under EAEU procedure
May: Completed 10th GMP mock audit
June: 1st drug dossier aligned with EAEU requirements
July: Acquisition of 210th Client
August: Completed registration of 50th medical device
November: Completion of 1200th project
November: Acquisition of 220th Client